Carsten Reinhardt

Carsten is a physician scientist who currently serves as Chief Development Officer and Managing Director at Immatics, a NASDAQ-listed company that is a pioneer in the field of tumor antigen identification (HLA-peptide complexes) and is focused on T-cell therapy (TCR-based ACT and bispecific TCR) against these targets. He has been intimately involved in successful fundraising and biopharmaceutical partnerships, including with Amgen, BMS, GSK, and Roche. Prior to joining Immatics, he was EVP and Chief Medical Officer at Micromet Inc., another pioneering NASDAQ-listed company that drove the field of bispecific antibodies to the first ever regulatory FDA approval of a bispecific antibody (BlincytoTM) leading to its acquisition in 2012 by Amgen for $1.6B. Carsten has studied medicine at Ludwig-Maximilians University in Munich and completed a Ph.D. at the Institute of Immunology in Munich in 1994. Additionally, he has been on scientific and supervisory boards to a variety of biopharma companies and is a visiting professor at the University of Basel in Pharmaceutical Medicine.